Low-Carb Diet for Type 2 Diabetes in Teens

A Low-Carb Approach to Treat Type 2 Diabetes in Pediatric Patients

Recruiting N/A Interventional Study
Type 2 Diabetes
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
12 – 18
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
University of Alabama at Birmingham · Other
Who this trial is looking for

This trial is looking for teenagers with type 2 diabetes to test how a low-carb diet works compared to a standard carbohydrate diet. Participants will be involved for 24 weeks.

Are You a Good Fit for This Trial?
Must be taking GLP-1MetforminSGLT-2 inhibitors

You may be able to join if

  • I am aged 12 to 18.
  • I have been diagnosed with type 2 diabetes for more than 3 months.
  • My HbA1C is between 6.5% and 8.5%.
  • My BMI is greater than the 85th percentile.
  • I have negative pancreatic autoantibodies.
  • I have been on a stable dose of anti-diabetic medications for 3 months.

You may not be able to join if

  • I am currently receiving insulin treatment.
  • I have renal impairment.
  • I have hepatic dysfunction.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

The purpose of this project is to test the effect of a low carb diet compared to standard carb diet among adolescents with T2D over a 24-week period.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 12-18 * Diabetes diagnosis \>3 months to ensure stable baseline glycemic control * HbA1C between 6.5- 8.5% * BMI \>85th percentile * Negative pancreatic autoantibodies * Stable dose of anti-diabetic drugs GLP-1, metformin, SGLT-2 inhibitors, for 3 months Exclusion Criteri…
Contacts

Ortal Resnick, MD

205-638-9107

oresnick@uabmc.edu

CONTACT